Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|October 2, 2012
- Pharmaceutical Technology-10-02-2012
- Volume 36
- Issue 10
Pharmaceutical Technology, October 2012 Issue (PDF)
Combination Drugs - Adding Up the Opportunities in Solid Dosage
Advertisement
Articles in this issue
almost 14 years ago
Integration of Less-Formal Risk Assessment Tools into Change Controlalmost 14 years ago
Technical Forum: Disposable Chromatographyalmost 14 years ago
Uniformity of Dosage Units Using Large Sample Sizesalmost 14 years ago
A World without R&Dalmost 14 years ago
Supplier Qualificationalmost 14 years ago
Determining Potency of Preclinical Dose Formulationsalmost 14 years ago
Report from IndiaAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5